Valuation: Vivesto AB

Market Cap 8.03Cr 78.73L 71.73L 66.4L 60.07L 1.13Cr 74Cr 1.18Cr 3.18Cr 40Cr 2.95Cr 2.89Cr 125.87Cr P/E 2026 *
-2.59x
P/E 2027 * -2.06x
Enterprise Value 6.93Cr 67.94L 61.9L 57.3L 51.83L 97.24L 63Cr 1.02Cr 2.75Cr 34Cr 2.55Cr 2.5Cr 108.62Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
52.67%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Vivesto AB

Manager TitleAgeSince
Chief Executive Officer 68 23/01/2023
Director of Finance/CFO 55 01/07/2026
Chief Tech/Sci/R&D Officer 39 01/01/2023
Director TitleAgeSince
Chairman 46 25/05/2022
Director/Board Member 61 26/09/2019
Director/Board Member 43 25/05/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-99.00% - - 78.73L
-2.29%-5.34%+28.73%+128.34% 1,20400Cr
-2.04%-5.78%+31.91%+78.34% 64TCr
-0.86%-3.71%+21.74%+105.02% 50TCr
-0.51%-1.38%+28.00%+68.29% 38TCr
-3.61%-9.62%+39.73%+30.53% 33TCr
+0.22%-4.54%+27.44%+51.85% 28TCr
+0.90%-3.70%-1.36%+33.23% 27TCr
-1.14%-6.05%+28.16%+65.35% 24TCr
-1.45%-0.85%+30.03%+120.72% 21TCr
Average -1.06%-4.40%+26.04%+75.74% 45TCr
Weighted average by Cap. -1.50%-4.71%+27.12%+88.22%

Financials

2026 *2027 *
Net sales - -
Net income -2.8Cr -27.47L -25.02L -23.16L -20.95L -39.31L -26Cr -41.14L -1.11Cr -14Cr -1.03Cr -1.01Cr -44Cr -3.9Cr -38.25L -34.85L -32.26L -29.18L -54.75L -36Cr -57.3L -1.55Cr -19Cr -1.44Cr -1.41Cr -61Cr
Net Debt -1.1Cr -10.79L -10L -9L -8L -15.44L -10Cr -16.16L -43.63L -5.45Cr -40.48L -39.63L -17Cr -2Cr -19.62L -17.87L -16.55L -14.97L -28.08L -18Cr -29.39L -79.33L -9.9Cr -73.6L -72.06L -31Cr
Logo Vivesto AB
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Employees
4